Global Cholera Vaccine Market (2022-2027)

company logo

company logo

Global Cholera Vaccine Market

Global Cholera Vaccine Market

Global Cholera Vaccine Market

Dublin, 16 May 2022 (GLOBE NEWSWIRE) — “Cholera Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunities and Forecast 2022-2027” report added to’s supply.

The global cholera vaccine market is valued at USD 4.36 million in 2021. Looking ahead, the market value is expected to reach USD 8.63 million by 2027, with a CAGR of 11.70% from 2022-2027. Given the uncertainty surrounding COVID-19, analysts are constantly tracking and assessing the direct and indirect impacts of the pandemic. These insights are included in the report as key market contributors.

Cholera is an intestinal disease caused by bacterial infection and spread through contaminated food and water. It can cause severe diarrhea, dehydration, abdominal pain, fever, increased heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is currently a global threat to public health and is preventable by vaccines. The cholera vaccine exposes the body to small doses of live cholera bacteria that help develop immunity to the disease. It can be taken orally or injected intradermally or intramuscularly in the body.

Cholera Vaccine Market Trends

Rising prevalence of cholera owing to poor sanitation is one of the major factors driving the market. In addition, the global use of polluted water for agriculture and fishing has increased. This is driving the growth of the market with increasing consumption on the street and fast food owing to the busy lifestyle of individuals.

In addition, water pollution has increased significantly due to the discharge of sewage and factory waste into lakes and rivers. As a result, people all over the world are eating contaminated seafood, which in turn contributes to the spread of cholera. In addition, increasing awareness of cholera through initiatives of non-governmental organizations (NGOs) and numerous immunization programs launched by several governments to reduce vaccine-preventable diseases are positively impacting the market. In addition, major market players are investing extensively in research and development (R&D) activities to provide more efficient and cost-effective cholera vaccines, which is expected to drive the market growth.

Key Market Segments

This report analyzes key trends in each segment of the global cholera vaccine market, along with forecasts at global, regional and country levels for 2022-2027. This report categorizes the market on the basis of vaccine type, product and end user.

By vaccine type:

By product:

End User Split:

By region:

  • North America

  • U.S.

  • Canada

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • other

  • Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

  • Russia

  • other

  • Latin America

  • Brazil

  • Mexico

  • other

  • Middle East and Africa

Competitive Landscape

The competitive landscape of the industry is also reviewed along with profiles of key players including Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Ebiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., PharmaChoice Canada Inc., Sanofi Corporation, Takeda Pharmaceutical Co., Ltd., and Valneva SE.

Key questions answered in this report

  • How has the global cholera vaccine market performed so far and how will it perform in the coming years?

  • How will COVID-19 impact the global cholera vaccine market?

  • What are the major regional markets?

  • What is the market segmentation based on vaccine type?

  • What is product-based market segmentation?

  • What is the market segmentation based on end user?

  • What are the various stages of the industry value chain?

  • What are the key drivers and challenges for the industry?

  • What is the structure of the global cholera vaccine market? Who are the main players?

  • How competitive is the industry?

Key topics covered:

1 Introduction

2 Scope and method

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Cholera Vaccine Market
5.1 Market Overview
5.2 Market performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Segmentation by Vaccine Type
6.1 Whole-cell V. cholera O1 with recombinant B subunits
6.1.1 Market Trend
6.1.2 Market Forecast
6.2 Kill oral O1 and O139
6.2.1 Market Trend
6.2.2 Market Forecast

7 Market Segmentation by Product
7.1 Duklar
7.1.1 Market Trend
7.1.2 Market Forecast
7.2 Shancor
7.2.1 Market Trend
7.2.2 Market Forecast
7.3 Wacker Chora
7.3.1 Market Trend
7.3.2 Market Forecast
7.4 Euvichol and Euvichol-Plus
7.4.1 Market Trend
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trend
7.5.2 Market Forecast

8 Market Segmentation by End Users
8.1 Hospitals and Clinics
8.1.1 Market Trend
8.1.2 Market Forecast
8.2 Research and Academic Laboratories
8.2.1 Market Trend
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trend
8.3.2 Market Forecast

9 Market Segmentation by Regions

10 SWOT Analysis

11 Value Chain Analysis

12 Porter’s Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Astellas Pharmaceuticals Inc. Company Overview Product Portfolio Finance SWOT Analysis
14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.) Company Overview Product Portfolio Finance SWOT Analysis
14.3.3 Emerging Biosolution Companies Company Overview Product Portfolio Finance SWOT Analysis
14.3.4 Ebiologics Ltd. Company Overview Product Portfolio Finance
14.3.5 Johnson & Johnson Company Overview Product Portfolio Finance SWOT Analysis
14.3.6 Merck & Co. Company Overview Product Portfolio Finance SWOT Analysis
14.3.7 Pfizer Inc. Company Overview Product Portfolio Finance SWOT Analysis
14.3.8 PharmaChoice Canada Inc. Company Overview Product Portfolio
14.3.9 Sanofi Corporation Company Overview Product Portfolio Finance SWOT Analysis
14.3.10 Takeda Pharmaceutical Co., Ltd. Company Overview Product Portfolio Finance SWOT Analysis
14.3.11 Vanierva SE Company Overview Product Portfolio Finance

For more information on this report, please visit


CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *